CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy
Executive Summary
In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.
You may also be interested in...
Roche Pushes Personalization With $2.4bn Foundation Buy-Out
By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.
'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy
Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.
ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs
Phase II data for antibody-drug conjugate polatuzumab vedotin in diffuse large B cell lymphoma suggest potential for a cure if the drug were given up front, Roche says on investor call after American Society of Hematology meeting.